# Immunological Basis for Mepolizumab Activity in COPD

> **NCT05320939** · PHASE2 · UNKNOWN · sponsor: **Temple University** · enrollment: 30 (estimated)

## Conditions studied

- COPD

## Interventions

- **DRUG:** Mepolizumab 100 MG

## Key facts

- **NCT ID:** NCT05320939
- **Lead sponsor:** Temple University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-04
- **Primary completion:** 2024-04
- **Final completion:** 2025-05
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2023-04-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05320939

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05320939, "Immunological Basis for Mepolizumab Activity in COPD". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05320939. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*